A cell kinetic study on medulloblastomas.
The cell kinetics of medulloblastoma were studied to define characteristic proliferation for comparison with other neuroectodermal tumors. Four patients with cerebellar medulloblastoma received 3H-thymidine intravenously 1 to 2 days before surgery. Biopsy specimens from each tumor were processed for autoradiography. The respective average labeling indices were 14.4%, 14.1%, and 11.2% in the three mid-cerebellar medulloblastomas and 8.0% in the cerebellar hemispheric medulloblastoma. The mean survival time with various treatments including radiation therapy before or after the study in these four patients was 6 years (range, 3-9 years). In contrast, patients with malignant gliomas that had a labeling index greater than 5% died within 1 year. This difference in survival was attributed to the greater sensitivity of medulloblastoma to radiation therapy.
D000293:Adolescent; D000328:Adult; D001345:Autoradiography; D001706:Biopsy; D002453:Cell Cycle; D002455:Cell Division; D002528:Cerebellar Neoplasms / Q000473:pathology* / Q000628:therapy; D002648:Child; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008527:Medulloblastoma / Q000473:pathology* / Q000556:secondary / Q000628:therapy; D008940:Mitotic Index; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D013936:Thymidine
D013936:Thymidine